- Went public, Sep 2020
- Raised $27M funding round, Oct 2024
- Raised $27.6M funding round, Feb 2020
About
Nyxoah is a medical device company focused on the development and commercialization of hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea (OSA). The company has developed a battery-free, leadless, minimally invasive neurostimulator capable of delivering bilateral hypoglossal nerve stimulation for patients with moderate to severe OSA who have failed at conventional positive airway pressure therapy. Nyxoahs therapy consists of a tiny neurostimulator that is implanted in the chin area in a minimally invasive surgery. The system, which is powered by a miniature external battery, is placed under the chin and stimulates the tongue nerve. In March 2019, Nyxoah received CE marking for its novel hypoglossal nerve stimulation therapy for treatment of obstructive sleep apnea. In January 2021, Nyxoah received CE mark magnetic resonance imaging (MRI) conditional labeling for the current Genio neurostimulation-based OSA therapy for treatment of obstructive sleep apnea.
Funding history · 7 rounds · $270.7M total
Q&A
- What is Nyxoah's primary focus?
- Nyxoah is a medical device company focused on the development and commercialization of hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea (OSA).
- When did Nyxoah go public on Euronext?
- Nyxoah went public on Euronext in September 2020 with an offering of $100,000,000 and a valuation of $423,000,000.
- When did Nyxoah go public on NASDAQ?
- Nyxoah went public on NASDAQ in July 2021.
- What was a significant regulatory milestone for Nyxoah in January 2021?
- In January 2021, Nyxoah received CE mark magnetic resonance imaging (MRI) conditional labeling for its Genio neurostimulation-based OSA therapy.
- What was Nyxoah's most recent funding round?
- Nyxoah's most recent funding round was in October 2024, raising $27,000,000.
- What was a key partnership announced by Nyxoah in September 2023?
- In September 2023, Nyxoah announced a partnership with ResMed in Germany.
- What was a significant leadership appointment for Nyxoah in November 2024?
- In November 2024, Nyxoah appointed John Landry as Chief Financial Officer.
- What was a notable product development for Nyxoah in July 2022?
- In July 2022, Nyxoah announced CE Mark approval for its Genio® 2.1 system.
- What was a recent regulatory submission by Nyxoah in July 2024?
- In July 2024, Nyxoah submitted the fourth and final module in its PMA Application for Genio to the US FDA.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nyxoah.com |
|---|---|
| linkedin.com/company/2521839 | |
| facebook.com/Nyxoah-SA-116970793034361 | |
| YouTube | youtube.com/channel/UCqdLKsG1TV4eGrHZRCpsBiA |
Identifiers & details
| Founded | 2008-1 |
|---|---|
| Employees (exact) | 197 |
| Offices | Mont-Saint-Guibert |
| Market cap | $197.9M |
| Status reason | Public on Euronext on Sep, 2020; Public on NASDAQ on Jul, 2021 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2020-09 | $100.0M | |||
| 2021-07 | ||||
| 2024-05 | $50.0M |